Maciej Banach: The ‘Metastatic’ Cardiovascular Threat We Can No Longer Ignore
Maciej Banach, Vice-Rector for the Collegium Medicum at John Paul II Catholic University of Lublin, shared a post on LinkedIn about a recent article he and his colleagues co-authored:
“Peripheral artery disease (PAD) is the most neglected atherosclerotic cardiovascular condition.
Most patients are diagnosed very late and require surgical intervention.
Even after successful procedures, many are not managed optimally:
Only a small percentage achieve LDL‑C targets, leaving them at high risk of recurrent events.
This is a final call to diagnose these patients as early as possible (which is straightforward) and to treat them effectively.
To appreciate you the scale of the risk, note that when significant atherosclerosis is present in the peripheral vasculature, the likelihood of concurrent atherosclerotic progression in two other vascular beds is the highest – ranging from 14% to as much as 70%!
For that reason we should always compare atherosclerosis to metastatic cancer.
Early, accurate diagnosis and prompt, intensive combination therapy are essential!
This is why we are now focusing strongly on PAD/ PVD patients. I’m pleased to share that the first article in this series, ‘Atherosclerosis Features in Rheumatic Diseases – Focus on Peripheral Artery Disease,’ has just been accepted (soon available – stay tuned!) by Frontiers in Immunology.
Thank you to the amazing team of young, ambitious colleagues who made this possible.”
Title: Atherosclerosis features in rheumatic diseases – focus on peripheral artery disease
Authors: Alexandr Ceasovschih, Alina Dima, Javier Rodríguez-Carrio, Anastasia Balta, Raluca-Elena Alexa, Bianca Morarasu, Catalina Lionte, Fotios Barkas, Maciej Banach, Victorita Sorodoc, Laurentiu Sorodoc
Read the Full Article on Frontiers in Immunology
More posts featuring Maciej Banach on Hemostasis Today.
-
May 27, 2026, 09:58Omid Seidizadeh: Take The EAHAD Survey on Access to Diagnosis and Treatment for VWD Europe
-
May 27, 2026, 09:51Richard Benjamin: RedeS Phase III Trial Reaches Major Milestone in Advancing Pathogen-Reduced RBCs for Transfusion
-
May 27, 2026, 04:47Daniel Torrent: The Overlooked Epidemic of Post-Thrombotic Syndrome
-
May 27, 2026, 04:45Graziella Pompei: Is Aspirin Still a Valid Alternative to Clopidogrel in PCI with DES Implantation?
-
May 27, 2026, 04:40Kausik Ray: Phase 1 Trial Highlights Anti-Inflammatory Effects of Ruvonoflast
-
May 27, 2026, 04:29Francisco Chacón-Lozsán: High-Sensitivity Troponin and the Evolving Management of NSTEMI
-
May 27, 2026, 04:14Michael R. Jaff: HI-PEITHO Trial and NEWS Score Insights on Advances for Intermediate-Risk Pulmonary Embolism
-
May 26, 2026, 16:45Ashley George: Take the Leap for Thrombosis UK
-
May 26, 2026, 16:40Hamed Helisaz: Machine Learning for Detecting Missing Heart Medications